reported the identification of a human HLAA2/AFP158-specific TCR (97), and a clinical trial using autologous T cells from HCC patients engineered with this AFP-specific TCR has been initiated and is ongoing (NCT03132792). The gene discussed is AFP; the disease is hepatocellular carcinoma.